Blog
0
From Devastating Setback in Treatment to Blessing
0

My family and I had been peppering him with questions after scans showed yet another recurrence; frantically in search of some understanding on how my ...

0
Lonsurf Plus Avastin ‘Provides Extra Time’ for People With Advanced CRC
0

The Food and Drug Administration's (FDA) recent approval of Lonsurf (trifluridine and tipiracil) plus Avastin (bevacizumab) for patients with metastatic ...

0
Phase 2 Trial to Investigate Novel Drug in ROS1-Positive Lung Cancer
0

A phase 2 trial will investigate a new drug for patients with ROS1-positive cancer. The phase 2 portion of the ARROS-1 clinical trial recently launched, ...

0
Stay on target – building a better resource for drug target evaluation – Cancer Research UK
0

Acceleration needs good evaluation At Cancer Research Horizons, our aim is to accelerate the discovery and development of new therapeutics, ensuring we ...

0
Adcetris Improves Lymphoma Outcomes, Regardless of PET Scan Results
0

Adding Adcetris (brentuximab vedotin) to frontline chemotherapy for patients with Hodgkin lymphoma led to improved outcomes, regardless of post-therapy PET ...

0
Can We Talk? Artificial Intelligence in the World of Cancer Care
0

Katie Coleman has utilized online support groups and developed a following via TikTok, X (formerly Twitter), Instagram, YouTube and her “Oncology ...

0
My Cancer Playlist
0

I’m frequently caught dancing in the aisles of the grocery store while listening to some song playing overhead. Folks passing generally smile and say ...

0
FDA Approves Aphexda Plus Filgrastim for Patients With Multiple Myeloma
0

The Food and Drug Administration (FDA) has approved Aphexda (motixafortide) in combination with bone marrow stimulant filgrastim (G-CSF) for the ...

0
Vitamin C/D Supplements Decrease Complications in Patients with AML
0

Vitamin C and D supplementation boosted quality of life for patients with acute myeloid leukemia, research showed. Patients with acute myeloid leukemia ...

0
Rybrevant Betters Outcomes in Certain Lung Cancer Populations
0

Rybrevant (amivantamab-vmjw) improved progression-free survival when given with or without lazertinib to patients with locally advanced or metastatic EGFR ...

0
Iclusig Boosts MRD-Negative Complete Response in Ph-Positive ALL
0

Adding Iclusig (ponatinib) to reduced-intensity chemotherapy increased minimal residual disease (MRD)-negative complete remission (CR) rate — meaning that ...

0
The UK’s Looming Cancer Catastrophe
0

If you would like this piece read to you, just click above There are now many more days, where I feel like giving up on fighting the cancer culture in ...

CML Alliance
Logo
Enable registration in settings - general
Compare items
  • Total (0)
Compare
0
Shopping cart